Medtronic’s most recent trend suggests a bullish bias. One trading opportunity on Medtronic is a Bull Put Spread using a strike $120.00 short put and a strike $110.00 long put offers a potential 8.7% return on risk over the next 29 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $120.00 by expiration. The full premium credit of $0.80 would be kept by the premium seller. The risk of $9.20 would be incurred if the stock dropped below the $110.00 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Medtronic is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Medtronic is bullish.
The RSI indicator is at 29.53 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Medtronic
Medtronic’s Evolut Aortic Valve Replacement Shows Positive Outcomes Even After Two Years
Tue, 18 May 2021 18:44:19 +0000
Medtronic Plc (NYSE: MDT) has announced the complete two-year outcomes from a low-risk trial comparing the Evolut transcatheter aortic valve replacement (TAVR) system to open-heart surgery in characteristically younger, healthier aortic stenosis patients. Data were presented at the EuroPCR 2021 e-Course. The results showed the Evolut TAVR platform was non-inferior to surgery for the primary endpoint of all-cause mortality or disabling stroke at two years (4.3% for TAVR versus 6.3% for surgery). At two years, the study showed that improved safety shown early on for TAVR was sustained over time. Better hemodynamic (blood flow) performance for TAVR with statistically significantly lower mean aortic valve gradient (9.0 mm Hg versus 11.7 mm Hg) was seen. A larger effective orifice area than surgery (2.2 cm2 versus 2.0 cm2) at two years was observed. Numerically lower rates of death in the TAVR arm (3.5% versus 4.4%), heart failure hospitalizations (5.3% versus 7.1%), and disabling stroke (1.5% versus 2.7%) compared to surgery at two years were reported. The prosthesis-patient mismatch was lower for TAVR than surgery at two years, with a difference of 2.1% versus 4.9% in the severe category. Valve thrombosis rates showed no signs of increase and remained low at two years. Price Action: MDT shares are up 0.76% at $126.49 during the market session on the last check Tuesday. See more from BenzingaClick here for options trades from BenzingaMedTech Round Up: Update On Lucira Health, Second Sight Medical ClearPoint Neuro, Medtronic, SientraMedTech Round Up: Update On Products By Conformis, Medtronic, Orthofix, Neovasc© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Medtronic Evolut™ TAVR System Shows Strong Performance at Two Years in Low Risk Trial
Tue, 18 May 2021 13:00:00 +0000
Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the complete two-year outcomes from the landmark Evolut Low Risk Trial comparing the minimally invasive Evolut™ transcatheter aortic valve replacement (TAVR) system to the gold standard of open-heart surgery in characteristically younger, healthier aortic stenosis patients. Presented virtually today as a late-breaking clinical trial at the EuroPCR 2021 e-Course, results showed the Evolut TAVR platform was non inferior to surgery for the primary endpoint of all-cause mortality or disabling stroke at two years (4.3% for TAVR versus 6.3% for surgery; p< 0.0001 for non-inferiority), and trended the same or lower on all critical events, confirming the earlier Bayesian statistical analysis presented at the American College of Cardiology (ACC) 68th Annual Scientific Session in 2019.
Late Breaking Data at EuroPCR Demonstrates Long-Term Benefits of Medtronic Radiofrequency Renal Denervation in Real-World Hypertensive Patients
Tue, 18 May 2021 12:00:00 +0000
Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced new clinical data from the Global SYMPLICITY Registry (GSR) indicating that renal denervation (RDN) with the Medtronic Symplicity™ Renal Denervation System was associated with clinically significant and sustained blood pressure reductions in a real-world hypertensive patient population through three years. Results from the prospective, single-arm, global, observational study are being presented as a Late-Breaking Clinical Trial session at the 2021 EuroPCR Annual Meeting.
Medtronic’s (MDT) Coronary Market Share Grows Amid Pandemic
Mon, 17 May 2021 14:17:02 +0000
In Gastrointestinal, Medtronic (MDT) is witnessing some modest share gains, driven in part by its partnership with the NHS in England.
New Survey Identifies Opportunity to Improve Shared Decision Making Between Cardiologists and Heart Valve Disease Patients
Fri, 14 May 2021 13:00:00 +0000
New findings from an American College of Cardiology’s (ACC) survey revealed more than half of cardiologists (57%) believe patient preparation may lead to better quality discussions around treatment options for heart valve disease (HVD). Results from the ACC CardioSurve panelist survey, sponsored by Medtronic (NYSE: MDT), and conducted by the American College of Cardiology, garnered responses from more than 150 cardiologists around key factors driving treatment choices for patients with symptomatic severe aortic stenosis. The data was published in the April 2021 Cardiology Magazine and will be presented Sunday during the virtual symposium at ACC’s 70th Annual Scientific Session, A Practical Approach to Shared Decision-Making when Treating HVD.
Follow Us on Facebook